Company news

Share this article:
Pfizer has received antitrust approval in its bid to purchase Encysive Pharmaceuticals for about $195 million. The company's offer to buy outstanding Encysive shares for $2.35 apiece expires at the end of March 31. The deal was announced last month.
Pfizer is looking to purchase Encysive to bolster is high blood pressure product portfolio.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.